Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
Synonyms
Rimonabant
Rimonabant hydrochloride
Brand Names
Zimulti
Acomplia
Indication
For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m<sup>2</sup>, or patients wih a BMI greater than 27 kg/m<sup>2</sup> with associated risk factors, such as type 2 diabetes or dyslipidaemia.
Categories
Agents producing tachycardia
Alimentary Tract and Metabolism
Anti-Obesity Agents
Antiobesity Preparations, Excl. Diet Products
Cannabinoid Receptor Antagonists
Cannabinoids and similars
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 Substrates
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
